Epidemiological Study in Subjects With Vulvovaginal Candidiases
NCT ID: NCT03064789
Last Updated: 2021-02-11
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
43 participants
OBSERVATIONAL
2016-12-29
2019-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Epidemiological Study About the Evolution of Patients Treated for an Acute Episode of Vulvovaginal Candidiasis
NCT02248506
Assessing the Safety, Immune Response, and Early Efficacy of a Candida Vaccine in Women With Recurrent Vulvovaginal Candidiasis: A Randomized Controlled Study
NCT06190509
Epidemiological Study of Vulvovaginal Candidiases Strain Types and Risk Factors Among Gynecological Outpatients in China
NCT06200389
Dose-Finding Study of Oral Ibrexafungep (SCY-078) vs. Oral Fluconazole in Subjects With Acute Vulvovaginal Candidiasis
NCT03253094
Study of FK463 in the Treatment of Candidemia or Invasive Candidiasis
NCT00036179
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Women with candidiases infection
Women that are prescribed treatment with clotrimazole: 500 mg. and probiotics (routine clinical practice)
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* With diagnosis and symptomatology of VVC
Exclusion Criteria
* Diabetes Mellitus
* Women witihin three months after a delivery or misbirth
* Women with vaginal or genital infection symptomatology other than candidiases that needs antibiotic treatment
* Vaginal probiotics use within last three months
* Undiagnosed abnormal genital hemorrhage
18 Years
50 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Dr. Santiago Palacios
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Dr. Santiago Palacios
MD - Gynecologyst
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Santiago Palacios, PI
Role: PRINCIPAL_INVESTIGATOR
Instituto Palacios
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Instituto Palacios
Madrid, , Spain
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
IP-01-2016
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.